Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen
- PMID: 6248876
- PMCID: PMC349530
- DOI: 10.1073/pnas.77.5.2979
Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen
Abstract
An antibody-secreting hybrid cell line was produced by fusion of mouse myeloma cells with splenocytes from mice immunized with virions of the B95-8 strain of Epstein-Barr Virus (EBV). The monoclonal IgG antibody was shown to have anti-EBV activity by the following criteria: (i) It reacted with the membranes and the cytoplasm of seven different EBV-producing lines, but with no nonproducing line. (ii) The individual cells identified by the murine antibody were shown to be the same cells identified by a human serum having anti-EBV activity. (iii) The antibody significantly reduced the infectivity of two independent strains of EBV (namely, P3HR1K and B95-8). The antigen being recognized was characterized by immunoprecipitations of radiolabeled EBV-producer cell lysates. A single glycoprotein with an estimated molecular weight of 250,000 was identified. It is concluded that neutralization of EBV can be achieved by an IgG-class monoclonal antibody directed against a single antigenic site on a 250,000-dalton glycoprotein, which is a constituent of the EBV virion.
Similar articles
-
Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein.Proc Natl Acad Sci U S A. 1982 Jan;79(2):616-20. doi: 10.1073/pnas.79.2.616. Proc Natl Acad Sci U S A. 1982. PMID: 6176998 Free PMC article.
-
Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.Proc Natl Acad Sci U S A. 1980 Sep;77(9):5307-11. doi: 10.1073/pnas.77.9.5307. Proc Natl Acad Sci U S A. 1980. PMID: 6254073 Free PMC article.
-
Monoclonal antibody specific for capsid antigen of Epstein-Barr virus.Med Microbiol Immunol. 1983;171(4):225-31. doi: 10.1007/BF02123496. Med Microbiol Immunol. 1983. PMID: 6304479
-
Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells.Cell. 1979 Jan;16(1):33-42. doi: 10.1016/0092-8674(79)90185-5. Cell. 1979. PMID: 217544
-
Epstein-Barr virus membrane antigens: characterization, distribution, and strain differences.J Virol. 1981 Jul;39(1):172-84. doi: 10.1128/JVI.39.1.172-184.1981. J Virol. 1981. PMID: 6268807 Free PMC article.
Cited by
-
Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.J Virol. 1988 Aug;62(8):2614-21. doi: 10.1128/JVI.62.8.2614-2621.1988. J Virol. 1988. PMID: 2839689 Free PMC article.
-
Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.J Virol. 1991 Feb;65(2):996-1001. doi: 10.1128/JVI.65.2.996-1001.1991. J Virol. 1991. PMID: 1846213 Free PMC article.
-
Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice.PLoS Pathog. 2018 Dec 6;14(12):e1007464. doi: 10.1371/journal.ppat.1007464. eCollection 2018 Dec. PLoS Pathog. 2018. PMID: 30521644 Free PMC article.
-
Complement receptor type two (CR2,CR21): a target for influencing the humoral immune response and antigen-trapping.Immunol Res. 1999;20(3):187-94. doi: 10.1007/BF02790402. Immunol Res. 1999. PMID: 10741859 Review.
-
The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.EMBO J. 2000 Jun 15;19(12):3080-9. doi: 10.1093/emboj/19.12.3080. EMBO J. 2000. PMID: 10856251 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials